141 related articles for article (PubMed ID: 21553235)
41. Significance of serum carcinoembryonic antigen and CA 15-3 in monitoring advanced breast cancer patients treated with systemic therapy: a large-scale retrospective study.
Kurebayashi J; Yamamoto Y; Tanaka K; Kohno N; Kurosumi M; Moriya T; Nishimura R; Ogawa Y; Taguchi T;
Breast Cancer; 2003; 10(1):38-44. PubMed ID: 12525762
[TBL] [Abstract][Full Text] [Related]
42. Use of TPS and CA 15-3 assays for monitoring chemotherapy in metastatic breast cancer patients.
Einarsson R; Lindman H; Bergh J
Anticancer Res; 2000; 20(6D):5089-93. PubMed ID: 11326674
[TBL] [Abstract][Full Text] [Related]
43. c-erbB-2 oncoprotein, CEA, and CA 15.3 in patients with breast cancer: prognostic value.
Molina R; Jo J; Filella X; Zanon G; Pahisa J; Mu noz M; Farrus B; Latre ML; Escriche C; Estape J; Ballesta AM
Breast Cancer Res Treat; 1998 Sep; 51(2):109-19. PubMed ID: 9879773
[TBL] [Abstract][Full Text] [Related]
44. The prognostic significance of preoperative tumor marker (CEA, CA15-3) elevation in breast cancer patients: data from the Korean Breast Cancer Society Registry.
Nam SE; Lim W; Jeong J; Lee S; Choi J; Park H; Jung YS; Jung SP; Bae SY
Breast Cancer Res Treat; 2019 Oct; 177(3):669-678. PubMed ID: 31312932
[TBL] [Abstract][Full Text] [Related]
45. Serum HER2 extra-cellular domain, S100ß and CA 15-3 levels are independent prognostic factors in metastatic breast cancer patients.
Darlix A; Lamy PJ; Lopez-Crapez E; Braccini AL; Firmin N; Romieu G; Thezenas S; Jacot W
BMC Cancer; 2016 Jul; 16():428. PubMed ID: 27387327
[TBL] [Abstract][Full Text] [Related]
46. Serum HER2 in combination with CA 15-3 as a parameter for prognosis in patients with early breast cancer.
Di Gioia D; Dresse M; Mayr D; Nagel D; Heinemann V; Stieber P
Clin Chim Acta; 2015 Feb; 440():16-22. PubMed ID: 25444743
[TBL] [Abstract][Full Text] [Related]
47. Serum tumor markers may precede instrumental response to chemotherapy in patients with metastatic cancer.
Massacesi C; Rocchi MB; Marcucci F; Pilone A; Galeazzi M; Bonsignori M
Int J Biol Markers; 2003; 18(4):295-300. PubMed ID: 14756546
[TBL] [Abstract][Full Text] [Related]
48. High levels of serum CA15-3 and residual invasive tumor size are associated with poor prognosis for breast cancer patients with non-pathological complete response after neoadjuvant chemotherapy.
Fujimoto Y; Higuchi T; Nishimukai A; Miyagawa Y; Kira A; Ozawa H; Bun A; Imamura M; Miyoshi Y
J Surg Oncol; 2018 Jul; 118(1):228-237. PubMed ID: 29936704
[TBL] [Abstract][Full Text] [Related]
49. Importance of CEA and CA 15-3 during disease progression in metastatic breast cancer patients.
Laessig D; Nagel D; Heinemann V; Untch M; Kahlert S; Bauerfeind I; Stieber P
Anticancer Res; 2007; 27(4A):1963-8. PubMed ID: 17649806
[TBL] [Abstract][Full Text] [Related]
50. Significance of serum tumor markers in monitoring advanced breast cancer patients treated with systemic therapy: a prospective study.
Kurebayashi J; Nishimura R; Tanaka K; Kohno N; Kurosumi M; Moriya T; Ogawa Y; Taguchi T
Breast Cancer; 2004; 11(4):389-95. PubMed ID: 15604995
[TBL] [Abstract][Full Text] [Related]
51. The objective measurement of remission and progression in metastatic breast cancer by use of serum tumour markers. European Group for Serum Tumour Markers in Breast Cancer.
Robertson JF; Jaeger W; Syzmendera JJ; Selby C; Coleman R; Howell A; Winstanley J; Jonssen PE; Bombardieri E; Sainsbury JR; Gronberg H; Kumpulainen E; Blamey RW
Eur J Cancer; 1999 Jan; 35(1):47-53. PubMed ID: 10211087
[TBL] [Abstract][Full Text] [Related]
52. Comparison of serum CA15-3 and CEA in breast cancer.
Hou MF; Huang TJ; Hsieh JS; Huang YS; Huang CJ; Chan HM; Wang JY; Chen YL; Jong SB; Yang CC
Gaoxiong Yi Xue Ke Xue Za Zhi; 1995 Dec; 11(12):660-6. PubMed ID: 8551526
[TBL] [Abstract][Full Text] [Related]
53. Quantitation of response to therapy in patients with metastatic breast carcinoma by serial analysis of plasma gross cystic disease fluid protein and carcinoembryonic antigen.
Silva JS; Leight GS; Haagensen DE; Tallos PB; Cox EB; Dilley WG; Wells SA
Cancer; 1982 Mar; 49(6):1236-42. PubMed ID: 6174201
[TBL] [Abstract][Full Text] [Related]
54. Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA).
Giovanella L; Ceriani L; Giardina G; Bardelli D; Tanzi F; Garancini S
Clin Chem Lab Med; 2002 Mar; 40(3):298-303. PubMed ID: 12005221
[TBL] [Abstract][Full Text] [Related]
55. The contribution of the CEA marker to CA 15.3 in the follow-up of breast cancer.
Valenzuela P; Mateos S; Tello E; López-Bueno MJ; Garrido N; Gaspar MJ
Eur J Gynaecol Oncol; 2003; 24(1):60-2. PubMed ID: 12691319
[TBL] [Abstract][Full Text] [Related]
56. Utility of a serum tumour marker panel in the post-operative follow-up of breast cancer patients with equivocal conventional radiological examinations.
Nicolini A; Carpi A; Ferrari P; Pieri L
Tumour Biol; 2003; 24(6):275-80. PubMed ID: 15004486
[TBL] [Abstract][Full Text] [Related]
57. Immunotherapy prolongs the serum CEA-TPA-CA15.3 lead time at the metastatic progression in endocrine-dependent breast cancer patients: a retrospective longitudinal study.
Nicolini A; Carpi A; Ferrari P; Rossi G
Cancer Lett; 2008 May; 263(1):122-9. PubMed ID: 18241981
[TBL] [Abstract][Full Text] [Related]
58. Comparison of a novel assay for breast cancer mucin to CA15-3 and carcinoembryonic antigen.
Daly L; Ferguson J; Cram GP; Hars V; George SL; McCarty KS; Bast RC
J Clin Oncol; 1992 Jul; 10(7):1057-65. PubMed ID: 1607912
[TBL] [Abstract][Full Text] [Related]
59. Plasma cell-free DNA chromosomal instability analysis by low-pass whole-genome sequencing to monitor breast cancer relapse.
Zhou H; Wang XJ; Jiang X; Qian Z; Chen T; Hu Y; Chen ZH; Gao Y; Wang R; Ye WW; Cao WM
Breast Cancer Res Treat; 2019 Nov; 178(1):63-73. PubMed ID: 31364001
[TBL] [Abstract][Full Text] [Related]
60. Any clinical benefit from the use of oncofoetal markers in the management of chemotherapy for patients with metastatic colorectal carcinomas?
Trillet-Lenoir V; Chapuis F; Touzet S; Barbier JY; Freyer G; Gaudin JL; Lombard-Bohas C; Valette PJ; Lledo G; Gouttebel MC; Boyer JD; Chassignol L; Hamon H; Claudel-Bonvoisin S; Leprince E; Amoyal P; Glehen O; Darnand P; Heilmann MO; Bleuse JP
Clin Oncol (R Coll Radiol); 2004 May; 16(3):196-203. PubMed ID: 15191007
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
